



# Human insulin-like growth factors binding protein 2,IGFBP-2 ELISA Kit

<b>Product Code</b>	CSB-E04588h
<b>Abbreviation</b>	IGFBP2
<b>Protein Biological Process 1</b>	Growth Factor
<b>Target Name</b>	insulin-like growth factor binding protein 2, 36kDa
<b>Uniprot No.</b>	P18065
<b>Alias</b>	IBP2, IGF-BP53,
<b>Product Type</b>	ELISA Kit
<b>Immunogen Species</b>	Homo sapiens (Human)
<b>Protein Biological Process 3</b>	Growth regulation
<b>Sample Types</b>	serum, plasma, tissue homogenates
<b>Detection Range</b>	0.78 ng/mL-50 ng/mL
<b>Sensitivity</b>	0.195 ng/mL
<b>Assay Time</b>	1-5h
<b>Sample Volume</b>	50-100ul
<b>Detection Wavelength</b>	450 nm
<b>Lead Time</b>	3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
<b>Research Area</b>	Signal Transduction
<b>Gene Names</b>	IGFBP2
<b>Tag Info</b>	quantitative
<b>Protein Description</b>	Sandwich

## Description

The product CSB-E04588h is a sandwich ELISA kit developed to measure concentrations of human IGFBP2 in serum, plasma, or tissue homogenates. This assay uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of IGFBP2 in samples. The color intensity is measured at 450 nm via a microplate reader.

IGFBP2 is considered a major regulator of IGFs bioavailability in the metabolic signaling pathway and controls the distribution, function, and activity of IGFs in the pericellular space. It is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth.



Abnormal overexpression of IGFBP2 is related to an aggressive phenotype of a broad range of human cancers, including glioma, ovarian, prostate, pancreatic, breast, lung, colorectal, melanoma, and liver cancer. High circulating IGFBP2 levels may serve as a useful diagnostic or prognostic tumor biomarker in many types of cancer and are closely linked to relapse and a poorer outlook for patients with cancer.

### Product Precision

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

### Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of human IGFBP-2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

?	Sample	Serum(n=4)
	Average %	97
1:5	Range %	91-105
	Average %	95
1:10	Range %	92-98
	Average %	92
1:20	Range %	86-99
	Average %	94
1:40	Range %	89-100


### Recovery

The recovery of human IGFBP-2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type	Average % Recovery	Range
Serum (n=5)	96	89-101
EDTA plasma (n=4)	94	88-99

### Typical

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



ng/ml	OD1	OD2	Average	Corrected
50	2.935	2.952	2.944	2.767
25	2.026	2.076	2.051	1.874
12.5	1.088	1.046	1.067	0.890
6.25	0.592	0.583	0.588	0.411
3.12	0.361	0.337	0.349	0.172
1.56	0.278	0.259	0.269	0.092
0.78	0.232	0.229	0.231	0.054
0	0.176	0.177	0.177	?

## Msds

{"0":{"fileurl":"https://www.cusabio.com/uploadfile/msds/MSDS CSB-E04588h.pdf","filename":"MSDS"}}